Health Economics›Waldenstroem macroglobulinemia›Relapsed or refractory non-randomized or retrospective data

Relapsed or refractory non-randomized or retrospective data

Waldenstroem macroglobulinemia · 12 regimens

Cost estimates only — modelled on a typical patient (BSA 1.7 m², 70 kg, CrCl 90 mL/min) using the cheapest available formulary presentation. Excludes vial wastage, facility fees, supportive care, and infusion consumables. Not for billing, formulary decisions, or clinical use.

Filters

Y-axis

Cost vs Efficacy · 7 points

Fully pricedPartial pricing

Regimen	Biomarker	Cost/cycle ↓	Cycle	PFS ↕	OS ↕	Est. cycles	Course cost ↕	Evidence
Alemtuzumab monotherapy Variant #03	—	R 267 680	7d	~15.0 mo	—	~1	~R 267 680 PFS proxy · indirect	—
Venetoclax monotherapy Variant #01	—	R 219 762	28d	—	—	~2	~R 439 524 indirect	—
RVR Variant #01	—	R 127 050	28d	—	—	~7	~R 366 184 indirect	—
Ibrutinib monotherapy Variant #01	—	R 81 964	28d	~44.1 mo	—	~2	~R 163 929 PFS proxy · indirect	15
Bortezomib and Rituximab (VR) Variant #01	—	R 58 571	60d	~12.8 mo	—	~5	~R 241 048 PFS proxy · indirect	1
Cladribine and Rituximab Variant #01	—	R 48 077	21d	—	—	~6	~R 288 462 indirect	—
Fludarabine and Rituximab (FR) Variant #01	—	R 34 157	28d	—	—	~6	~R 204 943 indirect	—
Bendamustine and Rituximab (BR) Variant #01	—	R 33 874	28d	~39.6 mo	—	~8	~R 270 994 PFS proxy · indirect	18
Everolimus monotherapy Variant #01	—	R 18 360	28d	~6.0 mo	~18.1 mo	~2	~R 36 719 PFS proxy · indirect	15
Bortezomib monotherapy Variant #03	—	R 6 762	21d	~30.3 mo	—	~8	~R 54 096 PFS proxy · indirect	5
Lenalidomide monotherapy Variant #01	—	R 2 178	28d	~30.8 mo	—	~24	~R 52 272 PFS proxy · indirect	2
Idelalisib monotherapy Variant #01 Partial	—	—	28d	—	—	~2	—	—

12 of 12 regimens shown